MedPlus Health's PAT dipped 25.70% yoy at Rs20.02crore

16 Feb 2022 , 11:10 AM

MedPlus Health Services Ltd. reported revenue of Rs933.45 crore for Q3FY22 against Rs800.99 crore for Q3FY21, up by 16.5% yoy. Revenue for the 9M ended December 2021 stood at Rs2,813.37 crore as compared to Rs2,263.50 crore for the 9M ended December 2020, registering a growth of 24.3% yoy.

The company’s operating EBITDA for Q3FY22 was reported at Rs36.61 crore as compared to Rs41.04 crore for Q3FY21, down by 10.80% yoy.

While operating EBITDA for 9M ended December 2021 gained 5.6% yoy at Rs144.42 crore against Rs136.79 crore.

EBITDA for the quarter under review stood at Rs68.91 crore against Rs67.01 crore for the previous corresponding quarter, marginally up by 2.6% yoy.

For the nine months ended December 2021, EBITDA stood at Rs238.42 crore against Rs173.75 crore for the corresponding period.

Its PAT for Q3FY22 was Rs20.02 crore against Rs22.77 crore for Q3FY21, down by 25.7% yoy. PAT for the 9M under consideration grew by a whopping 84.9% yoy at Rs83.29 crore as compared to Rs45.04 crore for quarter ended December 2020.

PAT margin settled at 2.2% for the current quarter and at 3% for the 9M ended December 2021. EBITDA Margin stood at 7.5% for Q3FY22 and 8.5% for 9M ended December 2021.

MedPlus Health was trading in the upper circuit today at Rs1,102.90, up by Rs42.70 or 4.03% against its previous closing price of Rs1,060.20. So far it touched day’s high and low of Rs1,113.55 and Rs1070 respectively.